I'm assuming that one of the benefits we have is we are targetting something with no known treatment and hopefully the path is a lot cheaper, assuming we have success in human phase 1 and 2 trials?
Even though i would like to make progress with imyc i guess that is an example of a drug that would need to go through the full testing regime, unless targetting myc is also considered as a new drug??
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-25
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |